BioVaxys and Procare Health Announce Broad CO-Development, JOINT Commercialization and Marketing Collaboration for Cancer and Viral Vaccines
USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU Co-Development of Vaccines for Cervical Cancer and HPV Right of First Refusal for US Marketing of Papilocare™ Vancouver, BC and Barcelona, Spain – February 10th, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCPK:LMNGF) (“BioVaxys”), the […]
BIOVAXYS SARS-CoV-2 VACCINE CANDIDATE BVX-0320 STIMULATES NEUTRALIZING ANTIBODIES TO LIVE COVID-19 VIRUS
Vancouver, BC – February 2, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) (“BioVaxys” or “Company”) is pleased to announce that its Covid-19 vaccine candidate, BVX-0320, elicits a neutralizing antibody response against SARS-CoV-2, as evidenced by further analysis of sera samples from a preclinical animal study (also known as the “murine model study”) of […]
COVID-T™ CLINICAL DEVELOPMENT PROGRAM INITIATED REGULATORY ADVISORY GROUP ENGAGED
Vancouver, BC – January 28, 2021 — BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV) (FRA:5LB) (“BioVaxys” or “Company”) is pleased to announce that it has initiated the clinical development program for Covid-T™, the Company’s novel diagnostic platform for detecting T-cell activity. The US Food and Drug Administration (“FDA”) has tentatively agreed to permit that BioVaxys […]
BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program and Vaccine Platform Expansion
Vancouver, BC – January 25, 2021 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, […]
BIOVAXYS VACCINE PLATFORM STIMULATES ROBUST T-CELL RESPONSE AGAINST VIRAL ANTIGENS
BVX-0320 Activates immune system Memory ‘helper ’ CD4+ and killer CD8+ T-cells against SARS-CoV-2 PotentIal for longer-term viral protection Vancouver, BC – December 21, 2020 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”) announced today that further analysis of the data from a preclinical animal study (also known as the “murine model […]
BioVaxys Provides Viral Vaccine Platform Program Update
Vancouver, BC – November 30, 2020 – BioVaxys Technology Corp. (CSE: BIOV) (OTCPK: LMNGF) (FSE: 5LB) (“BioVaxys” or “the Company”) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies […]
